Form 4: Vaxart Director Kevin Finney Receives Significant Equity Grants

Vaxart, Inc. Director Kevin Finney reported the acquisition of 6,103 common shares and 36,392 stock options through equity grants on June 13, 2025, as part of his compensation.

Summary

• Kevin Finney, a Director of Vaxart, Inc. (VXRT), reported changes in his beneficial ownership via a Form 4 filing.
• On June 13, 2025, Mr. Finney acquired 6,103 shares of common stock. These shares were granted upon the vesting of restricted stock units (RSUs) with a reported price of $0.
• The common shares are scheduled to vest on the earlier of the date immediately prior to the 2026 annual meeting of stockholders or June 13, 2026, which is the first anniversary of the grant date.
• Following this transaction, Mr. Finney directly beneficially owns a total of 38,103 shares of common stock.
• Additionally, on June 13, 2025, Mr. Finney acquired 36,392 stock options with an exercise price of $0.7 per share.
• These stock options are also set to vest on the earlier of the date immediately prior to the 2026 annual meeting of stockholders or June 13, 2026, and have an expiration date of June 13, 2035.
• Following this transaction, Mr. Finney directly beneficially owns 36,392 derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction (equity grant) which is a neutral event, reflecting standard compensation practices rather than a significant positive or negative operational or financial development.

Positives

• The grant of shares and options to a director aligns with standard executive compensation practices, indicating continued alignment of management interests with shareholder value.

Future Outlook

This document does not contain forward-looking statements or guidance regarding the company's future performance or strategy, as it is solely an insider transaction report.

Industry Context

This Form 4 filing, detailing an equity grant to a director, is a routine compensation event common across all industries, including the biotechnology sector where Vaxart operates. It does not provide specific insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• This document reports a standard equity compensation grant to a director. Such grants are common practice across publicly traded companies, including those in the biotechnology sector, to align director incentives with shareholder interests.
• The specific size and terms of the grant would typically be benchmarked against peer companies of similar size and stage, but this document does not provide the necessary context for such a detailed comparison.

Stakeholder Impact

• Shareholders: The grant of equity to a director aligns their interests with shareholders, potentially encouraging decisions that enhance long-term shareholder value. However, it also represents potential future dilution if new shares are issued upon vesting/exercise.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The granted common shares and stock options are scheduled to vest on the earlier of the date immediately prior to the 2026 annual meeting of stockholders or June 13, 2026.
• The stock options will expire on June 13, 2035.

Key Dates

Keywords

Vaxart, VXRT, SEC Form 4, insider transaction, equity grant, stock options, restricted stock units, director compensation, beneficial ownership